StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Calcifediol

25-Hydroxyvitamin D3

HCID 5283731
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
19356-17-3
Standard-SMILES
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12
InChIKey
JWUBBDSIWDLEOM-DTOXIADCSA-N
Summenformel
C27H44O2
Durchschnittliche Molmasse
400,6 g/mol
Monoisotopische Masse
400,33413065

Überblick

Calcidiol is a hydroxycalciol that is calciol in which the hydrogen at position 25 has been replaced by a hydroxy group. A prehormone resulting from the oxidation of calciol in the liver, it is further hydroxylated in the kidney to give calcitriol, the active form of vitamin D3. It has a role as a metabolite, a bone density conservation agent, a nutraceutical, a mouse metabolite and a human metabolite. It is a diol, a hydroxycalciol and a member of D3 vitamins.

Namen und Bezeichner

Bevorzugter Name
25-Hydroxyvitamin D3
IUPAC
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
Lokaler Name
Calcifediol
Englischer Name
CALCIFEDIOL
Summenformel
C27H44O2
Molmasse
400.65

Namen und Synonyme

CalcifediolCalcidiol25-hydroxyvitamin D319356-17-3Calcifediol anhydrousDidrogylCalcifediolumRayaldee5,6-cis-25-Hydroxyvitamin D3Cholecalciferol, 25-hydroxy-25-Hydroxycholescalciferol9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
Weitere Namen anzeigen
25-HYDROXYCHOLECALCIFEROLvitamin d3 25-hydroxy monohydrateA50912A 50912A-50912U-32070E
25-Hydroxycholecalciferol monohydrateDTXSID002272125(OH)D3T0WXW8F54E5,6-trans-25-HydroxycholescalciferolCHEBI:17933(3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

Datenbank-Bezeichner

CAS
19356-17-3、63283-36-3、64719-49-9
PubChem CID
5283731

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
6,2
Polarare Oberfläche (TPSA)
40,5 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
6
Schwere Atome
29
Formalladung
0
Komplexität
655

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceutical

LipidsLipids -> Sterol Lipids [ST] -> Secosteroids [ST03] -> Vitamin D3 and derivatives [ST0302]
SolubilityInsoluble
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physical DescriptionSolid
Collision Cross Section200.06 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

Physikochemische Eigenschaften

Schmelzpunkt
74 · 74-76oC
Siedepunkt
529.2 · 529.2±33.0 °C(Predicted)
Dichte
1.01 · 1.01±0.1 g/cm3(Predicted)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

Danger

H301+H311 (90.7%): Toxic if swallowed or in contact with skin [Danger Acute toxicity, oral; acute toxicity, dermal]

P260, P262, P264, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P316, P319, P320, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Danger

H301: Toxic if swallowed [Danger Acute toxicity, oral]

Gefahrenhinweise

Regulatory Information · 3 Einträge

Chemical: 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3.beta.,5Z,7E)-

Directive (EEC) No 524/1970 (Repealed by 32003R1831 And 32009R0767)

25-Hydroxycholecalciferol: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Calciferols: Human health tier II assessment
Hazard Classes and Categories · 2 Einträge

Acute Tox. 3 (93%)

Acute toxicity (ingestion) - category 3

Toxikologische Informationen

Exposure RoutesOral, readily absorbed.
Toxicity Summary · 1 Eintrag

Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

H - Systemic hormonal preparations, excl. sex hormones and insulins

A - Alimentary tract and metabolism

QH - Systemic hormonal preparations, excl. sex hormones and insulin

QA - Alimentary tract and metabolism

Pharmacodynamics · 1 Eintrag

Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.

Mechanism of Action · 1 Eintrag

Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.

Zugehörige Reaktionen

8
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 40440
HRID 40440als Produkt
Reaktionsgleichung von HRID 40441
HRID 40441als Produkt
Reaktionsgleichung von HRID 68176
HRID 68176als Edukt
Reaktionsgleichung von HRID 348784
HRID 348784als Edukt
Reaktionsgleichung von HRID 553331
HRID 553331als Edukt
Reaktionsgleichung von HRID 1706040
HRID 1706040als Produktals Edukt
Reaktionsgleichung von HRID 2259555
HRID 2259555als Produkt
Reaktionsgleichung von HRID 2419197
HRID 2419197als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
DTXSID
DTXSID0022721
ChEMBL
CHEMBL1040、CHEMBL3544909
ChEBI
CHEBI:17933
UNII
T0WXW8F54E
EC Number
242-990-9
Nikkaji
J9.697K
Flammpunkt
14 °C · 14 °C
storage temp.
-20 °C · -20°C
Löslichkeit
20 mg/ml; · DMF: 20 mg/ml; DMSO: 10 mg/ml; Ethanol: 20 mg/ml; Ethanol:PBS (pH 7.2)(1:2): 0.3 mg/ml
pka
14.74 · 14.74±0.20(Predicted)
Aggregatzustand
White to off-white crystalline solid.
Farbe
White to off-white
Biologische Quelle
synthetic
Stabilität
Light Sensitive, Temperature Sensitive
Major Application
detection
InChIKey
JWUBBDSIWDLEOM-DTOXIADCSA-N
SMILES
C[C@]12CCC/C(=C\C=C3\C[C@@H](O)CCC\3=C)/[C@]1([H])CC[C@]2([H])[C@H](C)CCCC(O)(C)C |&1:1,10,16,20,22,r|
Signs and Symptoms · 1 Eintrag

Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Sicherheitsdaten

F
8-10-19
wgk
3
ridadr
UN 2811 6.1/PG 2
hs_code
29362900
risk_code
28-48/25-26-24/25-11
hazard_code
T+,F
safety_code
28-36/37-45-16-7
hazard_class
6.1
packing_group
Ⅱ
Speicherklasse
3 - Flammable liquids
Hazard Classifications
Eye Irrit. 2Flam. Liq. 2
Biological Half-Life288 hours
Metabolism/Metabolites · 2 Einträge

Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.

Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3. Half Life: 288 hours

FDA Pharmacological Classification · 6 Einträge

T0WXW8F54E

CALCIFEDIOL ANHYDROUS

Chemical Structure [CS] - Cholecalciferol

Established Pharmacologic Class [EPC] - Vitamin D3 Analog

Calcifediol anhydrous is a Vitamin D3 Analog.

CALCIFEDIOL

MeSH Pharmacological Classification · 2 Einträge

Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Absorption, Distribution and ExcretionReadily absorbed.
Tissue LocationsEpidermis
Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 1 Eintrag

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Anwendungen

VerwendenA metabolite of Vitamin D. The principal circulating form of vitamin D3, formed in the liver by hydroxylation at C-25. Calcium regulator.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

19-Diol 3-acetate
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A hydroxycalciol that is calciol in which the hydrogen at position 25 has been replaced by a hydroxy group. A prehormone resulting from the oxidation of calciol in the liver, it is further hydroxylated in the kidney to give calcitriol, the active form of v tamin D3.